Molecular alterations of EGFR and PTEN in prostate cancer: Association with high-grade and advanced-stage carcinomas

Modern Pathology

Volumn 23, Issue 5, 2010, Pages 703-712

  De Muga, Silvia ^a,b,c   Hernández, Silvia ^a   Agell, Laia ^b,c   Salido, Marta ^b,c   Juanpere, Nuria ^b,c   Lorenzo, Marta ^b   Lorente, José A ^b,c   Serrano, Sergio ^b,c   Lloreta, Josep ^a,b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

EGFR; FISH; Mutation; Overexpression; Prostate cancer; PTEN

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CAUCASIAN; CHROMOSOME 7; CONTROLLED STUDY; DNA POLYMORPHISM; FLUORESCENCE IN SITU HYBRIDIZATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SOMATIC MUTATION;

ADENOCARCINOMA; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 77952009539     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.45     Document Type: Article

References (51)

1. Normanno N, de Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
3. Sibilia M, Kroismayr R, Lichtenberger BM, et al. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007;75:770-787.
4. Sebastian S, Settleman J, Reshkin SJ, et al. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 2006;1766:120-139.
5. di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgenindependence in human prostate cancer. Clin Cancer Res 2002;8:3438-3444.
6. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
7. Janne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006;12:4416s-4420s.
8. Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006;12:4283-4287.
9. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009;15:1133-1139.
10. Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007;109:1561-1569.
11. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:2879-2882.
12. Nagahara H, Mimori K, Ohta M, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005;11:1368-1371. (Pubitemid 40315215)
13. Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007;13:6579-6584.
14. Cho KS, Lee JS, Cho NH, et al. Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer. Prostate 2008;68:803-808.
15. Douglas DA, Zhong H, Ro JY, et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci 2006;11:2518-2525.
16. Fang J, Ding M, Yang L, et al. PI3K/PTEN/AKT signaling regulates prostate adenocarcinoma angiogenesis. Cell Signal 2007;19:2487-2497.
17. Gao N, Zhang Z, Jiang BH, et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003;310:1124-1132.
18. di Cristofano A, Pandolfi PP. The multiple roles of PTEN in adenocarcinoma suppression. Cell 2000;100:387-390.
19. Jiang BH, Liu LZ. PI3K/PTEN signaling in adenocarcinomaigenesis and angiogenesis. Biochim Biophys Acta 2008;1784:150-158.
20. Liu W, Zhou Y, Reske SN, et al. PTEN mutation: many birds with one stone in adenocarcinomaigenesis. Anticancer Res 2008;28:3613-3619.
21. Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett 2006;241:184-196.
22. Liu W, Chang B, Sauvageot J, et al. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer 2006;45:1018-1032.
23. Kwabi-Addo B, Giri D, Schmidt K, et al. Haploinsufficiency of the Pten adenocarcinoma suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001;98:11563-11568.
24. Schmitz M, Grignard G, Margue C, et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007;120:1284-1292.
25. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-685.
26. Dong JT, Sipe TW, Hyytinen ER, et al. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 1998;17:1979-1982.
27. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006;97:433-447.
28. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-7474.
29. Pesche S, Latil A, Muzeau F, et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998;16:2879-2883.
30. Whang YE, Wu X, Suzuki H, et al. Inactivation of the adenocarcinoma suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998;95:5246-5250.
31. Sarker D, Reid AH, Yap TA, et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009;15:4799-4805.
32. Hernandez S, de Muga S, Agell L, et al. FGFR3 mutations in prostate cancer: association with lowgrade adenocarcinomas. Mod Pathol 2009;22:848-856.
33. Cai CQ, Peng Y, Buckley MT, et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 2008;27:3201-3210.
34. Abdel-Rahman MH, Yang Y, Zhou XP, et al. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 2006;24:288-295.
35. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-3940.
36. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
37. Brandt B, Meyer-Staeckling S, Schmidt H, et al. Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res 2006;12:7252-7260.
38. Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009;63:315-321.
39. Zhang X, Chang A. Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. J Med Genet 2007;44:166-172.
40. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-1824.
41. Shuch B, Mikhail M, Satagopan J, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 2004;22:4725-4729.
42. Zellweger T, Ninck C, Bloch M, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005;113:619-628.
43. Ibrahim GK, Kerns BJ, MacDonald JA, et al. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 1993;149:170-173.
44. Morris GL, Dodd JG. Epidermal growth factor receptor mRNA levels in human prostatic adenocarcinomas and cell lines. J Urol 1990;143:1272-1274.
45. Turkeri LN, Sakr WA, Wykes SM, et al. Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. Prostate 1994;25:199-205.
46. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004;15:171-176.
47. Uzoh CC, Perks CM, Bahl A, et al. PTEN-mediated pathways and their association with treatment-resistant prostate cancer. BJU Int 2009;104:556-561.
48. Feilotter HE, Nagai MA, Boag AH, et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998;16:1743-1748.
49. McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-4296.
50. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-1568.
51. Ratnacaram CK, Teletin M, Jiang M, et al. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci USA 2008;105:2521-2526.